The value of the deal depends on our results. Given that there...

The value of the deal depends on our results.

Given that there was a weed out of those who responded to standard care I'm expecting pretty good results.

If the results are good, it's an easy product to sell, as it saves health authorities time and money. Patients heal faster and have less pain. Easy to use and administer.

No safety issues (it's the patient's own body that is doing the healing with ftt's help) and cheap to manufacture. Hence there's an easy market worth $100's millions for the partner.

I was always expecting a deal, but I could now imagine a take over. Given a rise after good results, I would expect a takeover to be around the $300m mark, maybe more. If the results are stunning (and when one breaks down the snippets we have received, that is possible) then a price nearer $1b becomes a possibility.

There's still risk, and we might not show any improvement. But I think that's unlikely. Great odds imho, with a down side of 1x maximum and an upside of up to 20x.